{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:40:32Z","timestamp":1768441232978,"version":"3.49.0"},"reference-count":30,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2019-0015_s_001a_w2aab3b7b1b1b6b1aab1c16b1Aa\">\n                    <jats:title id=\"d2883964e415_w2aab3b7b1b1b6b1aab1c16b1aAa\">Background<\/jats:title>\n                    <jats:p>In peritoneal surface malignancy (PSM), in spite of optimal cytoreductive surgery (CRS), majority of recurrences that occur are intraperitoneal. In patients with PSM, studies employing fluorescent imaging and microscopic examination have shown normal looking peritoneum may harbor active disease. This study was done to assess the recurrence pattern, oncological outcomes, and morbidity and mortality of the extent of peritonectomy in patients who underwent total parietal peritonectomy (TPP) or involved field peritonectomy (IFP) as a part of the procedure during CRS and hyperthermic intraperitoneal chemotherapy (HIPEC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0015_s_001b_w2aab3b7b1b1b6b1aab1c16b2Aa\">\n                    <jats:title id=\"d2883964e424_w2aab3b7b1b1b6b1aab1c16b2aAa\">Methods<\/jats:title>\n                    <jats:p>This was a retrospective analysis of prospectively collected data, from February 2013 to December 2017. A total of 163 patients with PSM underwent TPP or IFP with CRS plus HIPEC. Their oncological outcomes, recurrence pattern, postoperative morbidity and mortality were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0015_s_001c_w2aab3b7b1b1b6b1aab1c16b3Aa\">\n                    <jats:title id=\"d2883964e433_w2aab3b7b1b1b6b1aab1c16b3aAa\">Results<\/jats:title>\n                    <jats:p>Of the 163 cases, the primary organs of origin were ovary, colorectal, appendicular pseudomyxoma, stomach, mesothelioma and others (67.4%, 16.5%, 6.1%, 4.9%, 2% and 2%), respectively. TPP was performed in 70 patients and IFP in 93 patients. TPP group had higher mean PCI (16 vs. 14), longer duration of surgery (11 vs. 9\u2006h), and more blood loss (1,243 vs. 675\u2006mL). Overall G3\u2013G4 morbidity was comparable in both groups (42.8% vs. 33.3%) as was mortality (5.7% vs. 4.4%). Kaplan\u2013Meier analysis showed that with a median follow-up of 45\u2006months, TPP group had a recurrence-free survival (RFS) of 26\u2006months and overall survival (OS) was yet to be achieved, whereas the IFP group had a RFS and OS of 21 and 43\u2006months, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0015_s_001d_w2aab3b7b1b1b6b1aab1c16b4Aa\">\n                    <jats:title id=\"d2883964e442_w2aab3b7b1b1b6b1aab1c16b4aAa\">Conclusions<\/jats:title>\n                    <jats:p>Performing TPP reduces the chance of missing the microscopic disease, therefore can minimize local recurrence, and better oncological outcomes. TPP can be performed with acceptable morbidity and mortality, at the cost of increased duration of surgery and higher blood loss.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2019-0015","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T12:06:37Z","timestamp":1573128397000},"source":"Crossref","is-referenced-by-count":12,"title":["Impact of extent of parietal peritonectomy on oncological outcome after cytoreductive surgery and HIPEC"],"prefix":"10.1515","volume":"4","author":[{"given":"S.P.","family":"Somashekhar","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology , Manipal Comprehensive Cancer Centre, Manipal Hospital , Bengaluru India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.R.","family":"Ashwin","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology , Manipal Comprehensive Cancer Centre, Manipal Hospital , Bengaluru India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramya","family":"Yethadka","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology , Manipal Comprehensive Cancer Centre, Manipal Hospital , Bengaluru India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabber S.","family":"Zaveri","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology , Manipal Comprehensive Cancer Centre, Manipal Hospital , Bengaluru India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay K","family":"Ahuja","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology , Manipal Comprehensive Cancer Centre, Manipal Hospital , Bengaluru India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Rauthan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology , Manipal Comprehensive Cancer Center, Manipal Hospital , Bangalore , Karnataka , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar C.","family":"Rohit","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology , Manipal Comprehensive Cancer Centre, Manipal Hospital , Bengaluru India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"2025120909222925102_j_pp-2019-0015_ref_001_w2aab3b7b1b1b6b1ab1b7b1Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995;221:29\u201342.10.1097\/00000658-199501000-000047826158","DOI":"10.1097\/00000658-199501000-00004"},{"key":"2025120909222925102_j_pp-2019-0015_ref_002_w2aab3b7b1b1b6b1ab1b7b2Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999;43:S15\u201325.10.1007\/s00280005109310357554","DOI":"10.1007\/s002800051093"},{"key":"2025120909222925102_j_pp-2019-0015_ref_003_w2aab3b7b1b1b6b1ab1b7b3Aa","doi-asserted-by":"crossref","unstructured":"Di Giorgio A, De Iaco P, De Simone M, Garofalo A, Scambia G, Pinna AD, et\u2009al. Cytoreduction (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: retrospective Italian multicenter observational study of 511 cases. Ann Surg Oncol 2016;24:914\u201322.27896512","DOI":"10.1245\/s10434-016-5686-1"},{"key":"2025120909222925102_j_pp-2019-0015_ref_004_w2aab3b7b1b1b6b1ab1b7b4Aa","doi-asserted-by":"crossref","unstructured":"Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et\u2009al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012;30:2449\u201356.10.1200\/JCO.2011.39.716622614976","DOI":"10.1200\/jco.2012.30.4_suppl.532"},{"key":"2025120909222925102_j_pp-2019-0015_ref_005_w2aab3b7b1b1b6b1ab1b7b5Aa","doi-asserted-by":"crossref","unstructured":"Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol 2009;100:321\u20138.10.1002\/jso.2138819697439","DOI":"10.1002\/jso.21388"},{"key":"2025120909222925102_j_pp-2019-0015_ref_006_w2aab3b7b1b1b6b1ab1b7b6Aa","doi-asserted-by":"crossref","unstructured":"Liberale G, Vankerckhove S, Caldon MG, Ahmed B, Moreau M, Nakadi IE, et\u2009al. Group R&D for the clinical application of fluorescence imaging of the Jules Bordet\u02bcs Institute. Fluorescence imaging after indocyanine green injection for detection of peritoneal metastases in patients undergoing cytoreductive surgery for peritoneal carcinomatosis from colorectal cancer: a pilot study. Ann Surg 2016;264:1110\u20135.","DOI":"10.1097\/SLA.0000000000001618"},{"key":"2025120909222925102_j_pp-2019-0015_ref_007_w2aab3b7b1b1b6b1ab1b7b7Aa","doi-asserted-by":"crossref","unstructured":"Boogerd LS, Hoogstins CE, Schaap DP, Kusters M, Handgraaf HJ, van der Valk MJ, et\u2009al. Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study. Lancet Gastroenterol Hepatol 2018;3:181\u201391.2936143510.1016\/S2468-1253(17)30395-3","DOI":"10.1016\/S2468-1253(17)30395-3"},{"key":"2025120909222925102_j_pp-2019-0015_ref_008_w2aab3b7b1b1b6b1ab1b7b8Aa","doi-asserted-by":"crossref","unstructured":"Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol 2012;19:1416\u201324.10.1245\/s10434-012-2237-222302266","DOI":"10.1245\/s10434-012-2237-2"},{"key":"2025120909222925102_j_pp-2019-0015_ref_009_w2aab3b7b1b1b6b1ab1b7b9Aa","doi-asserted-by":"crossref","unstructured":"Somashekhar SP, Ashwin KR, Rohit K, Ramya Y, Shabber Z, Amit R. Comparison of outcomes following complete and selective parietal peritonectomy during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer: a study by Indian Society of Peritoneal Surface Malignancies (ISPSM). Indian J Gynecol Oncolog 2018;16:71.","DOI":"10.1007\/s40944-018-0241-6"},{"key":"2025120909222925102_j_pp-2019-0015_ref_010_w2aab3b7b1b1b6b1ab1b7c10Aa","doi-asserted-by":"crossref","unstructured":"Yan TD, Cao CQ, Munkholm-Larsen S. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol 2010;2:109\u201316.2116092910.4251\/wjgo.v2.i2.109","DOI":"10.4251\/wjgo.v2.i2.109"},{"key":"2025120909222925102_j_pp-2019-0015_ref_011_w2aab3b7b1b1b6b1ab1b7c11Aa","doi-asserted-by":"crossref","unstructured":"Br\u00fccher BL, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, et al. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC \u2013 overview and basics. Cancer Invest 2012;30(3):209\u201324.10.3109\/07357907.2012.65487122360361","DOI":"10.3109\/07357907.2012.654871"},{"key":"2025120909222925102_j_pp-2019-0015_ref_012_w2aab3b7b1b1b6b1ab1b7c12Aa","doi-asserted-by":"crossref","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HW, Hermans RH, et\u2009al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378:230\u201340.10.1056\/NEJMoa170861829342393","DOI":"10.1056\/NEJMoa1708618"},{"key":"2025120909222925102_j_pp-2019-0015_ref_013_w2aab3b7b1b1b6b1ab1b7c13Aa","doi-asserted-by":"crossref","unstructured":"Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, et\u2009al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 2015;22:1570\u20135.10.1245\/s10434-014-4157-925391263","DOI":"10.1245\/s10434-014-4157-9"},{"key":"2025120909222925102_j_pp-2019-0015_ref_014_w2aab3b7b1b1b6b1ab1b7c14Aa","doi-asserted-by":"crossref","unstructured":"Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et\u2009al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737\u201343.1455129310.1200\/JCO.2003.04.187","DOI":"10.1200\/JCO.2003.04.187"},{"key":"2025120909222925102_j_pp-2019-0015_ref_015_w2aab3b7b1b1b6b1ab1b7c15Aa","unstructured":"Esquivel J, Farinetti A, Sugarbaker PH. Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to proceed. G Chir 1999;20:81\u20136.10217864"},{"key":"2025120909222925102_j_pp-2019-0015_ref_016_w2aab3b7b1b1b6b1ab1b7c16Aa","doi-asserted-by":"crossref","unstructured":"Somashekhar SP, Ashwin KR, Rohit K, Natraj N, Ramya Y, Shabber Z, et\u2009al. Standardization of patient selection and hyperthermic intraperitoneal chemotherapy protocol for peritoneal surface malignancy in Indian patients. Indian J Gynecol Oncolog 2017;15:55\u201363.10.1007\/s40944-017-0154-9","DOI":"10.1007\/s40944-017-0154-9"},{"key":"2025120909222925102_j_pp-2019-0015_ref_017_w2aab3b7b1b1b6b1ab1b7c17Aa","doi-asserted-by":"crossref","unstructured":"Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et\u2009al. The Clavien\u2013Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250:187\u201396.1963891210.1097\/SLA.0b013e3181b13ca2","DOI":"10.1097\/SLA.0b013e3181b13ca2"},{"key":"2025120909222925102_j_pp-2019-0015_ref_018_w2aab3b7b1b1b6b1ab1b7c18Aa","doi-asserted-by":"crossref","unstructured":"Huang CQ, Min Y, Wang SY, Yang XJ, Liu Y, Xiong B, et\u2009al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget 2017;8:55657\u201383.28903452","DOI":"10.18632\/oncotarget.17497"},{"key":"2025120909222925102_j_pp-2019-0015_ref_019_w2aab3b7b1b1b6b1ab1b7c19Aa","doi-asserted-by":"crossref","unstructured":"Chang SJ, Bristow RE, Chi DS, Cilby WA. Role of aggressive surgical cytoreduction in advanced ovarian cancer. J Gynecol Oncol 2015;26:336\u201342.10.3802\/jgo.2015.26.4.33626197773","DOI":"10.3802\/jgo.2015.26.4.336"},{"key":"2025120909222925102_j_pp-2019-0015_ref_020_w2aab3b7b1b1b6b1ab1b7c20Aa","unstructured":"Sugarbaker PH. Cytoreductive surgery using peritonectomy and visceral resections for peritoneal surface malignancy. Transl Gastrointest Cancer 2013;2:54\u201374."},{"key":"2025120909222925102_j_pp-2019-0015_ref_021_w2aab3b7b1b1b6b1ab1b7c21Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer. Cancer Treat Res 1996;81:75\u201387.10.1007\/978-1-4613-1245-1_88834577","DOI":"10.1007\/978-1-4613-1245-1_8"},{"key":"2025120909222925102_j_pp-2019-0015_ref_022_w2aab3b7b1b1b6b1ab1b7c22Aa","doi-asserted-by":"crossref","unstructured":"Kim HS, Bristow RE, Chang SJ. Total parietal peritonectomy with en bloc pelvic resection for advanced ovarian cancer with peritoneal carcinomatosis. Gynecol Oncol 2016;143:688\u20139.2774373710.1016\/j.ygyno.2016.10.014","DOI":"10.1016\/j.ygyno.2016.10.014"},{"key":"2025120909222925102_j_pp-2019-0015_ref_023_w2aab3b7b1b1b6b1ab1b7c23Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am 2003;12:649\u201371.1456702310.1016\/S1055-3207(03)00037-1","DOI":"10.1016\/S1055-3207(03)00037-1"},{"key":"2025120909222925102_j_pp-2019-0015_ref_024_w2aab3b7b1b1b6b1ab1b7c24Aa","unstructured":"Sugarbaker PH. Technical handbook for the integration of cytoreductive surgery and perioperative intraperitoneal chemotherapy into the surgical management of gastrointestinal and gynaecologic malignancy, 4th ed. Grand Rapids: Ludann Company, 2005:12\u201324."},{"key":"2025120909222925102_j_pp-2019-0015_ref_025_w2aab3b7b1b1b6b1ab1b7c25Aa","doi-asserted-by":"crossref","unstructured":"Fung-Kee-Fung M, Provencher D, Rosen B, Hoskins P, Rambout L, Oliver T, et\u2009al. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care. Gynecol Oncol 2007;105:747\u201356.1736852210.1016\/j.ygyno.2007.02.015","DOI":"10.1016\/j.ygyno.2007.02.015"},{"key":"2025120909222925102_j_pp-2019-0015_ref_026_w2aab3b7b1b1b6b1ab1b7c26Aa","doi-asserted-by":"crossref","unstructured":"Shen P, Levine EA, Hall J, Case D, Russell G, Fleming R, et\u2009al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003;138:26\u201333.10.1001\/archsurg.138.1.2612511145","DOI":"10.1001\/archsurg.138.1.26"},{"key":"2025120909222925102_j_pp-2019-0015_ref_027_w2aab3b7b1b1b6b1ab1b7c27Aa","doi-asserted-by":"crossref","unstructured":"Ahmad SA, Kim J, Sussman JJ, Soldano DA, Pennington LJ, James LE, et\u2009al. Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. Ann Surg Oncol 2004;11:387\u201392.10.1245\/ASO.2004.09.00715070598","DOI":"10.1245\/ASO.2004.09.007"},{"key":"2025120909222925102_j_pp-2019-0015_ref_028_w2aab3b7b1b1b6b1ab1b7c28Aa","doi-asserted-by":"crossref","unstructured":"Chua TC, Saxena A, Schellekens JF, Liauw W, Yan TD, Fransi S, et\u2009al. Morbidity and mortality outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: towards a new perspective of this treatment. Ann Surg 2010;251:101\u20136.10.1097\/SLA.0b013e3181b5ae43","DOI":"10.1097\/SLA.0b013e3181b5ae43"},{"key":"2025120909222925102_j_pp-2019-0015_ref_029_w2aab3b7b1b1b6b1ab1b7c29Aa","doi-asserted-by":"crossref","unstructured":"Kusamura S, Baratti D, Deraco M. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies. Ann Surg 2012;255:348\u201356.10.1097\/SLA.0b013e3182436c2822202584","DOI":"10.1097\/SLA.0b013e3182436c28"},{"key":"2025120909222925102_j_pp-2019-0015_ref_030_w2aab3b7b1b1b6b1ab1b7c30Aa","doi-asserted-by":"crossref","unstructured":"Hynninen J, Lavonius M, Oksa S, Gr\u00e9nman S, Carp\u00e9n O, Auranen A. Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? Gynecol Oncol 2013;128:229\u201332.2314207610.1016\/j.ygyno.2012.11.007","DOI":"10.1016\/j.ygyno.2012.11.007"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/4\/4\/article-20190015.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0015\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0015\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:58:28Z","timestamp":1765277908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0015\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,11,2]]},"published-print":{"date-parts":[[2019,11,26]]}},"alternative-id":["10.1515\/pp-2019-0015"],"URL":"https:\/\/doi.org\/10.1515\/pp-2019-0015","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"article-number":"20190015"}}